Kathryn Eve Lewandowski, Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Psychotic Disorders | 36 | 2024 | 3276 | 4.700 |
Why?
|
| Bipolar Disorder | 31 | 2024 | 5130 | 3.360 |
Why?
|
| Schizophrenia | 33 | 2024 | 6983 | 2.880 |
Why?
|
| Cognition Disorders | 14 | 2020 | 3980 | 1.980 |
Why?
|
| Affective Disorders, Psychotic | 3 | 2019 | 187 | 1.270 |
Why?
|
| Schizophrenic Psychology | 13 | 2024 | 1649 | 1.230 |
Why?
|
| Neuropsychological Tests | 10 | 2024 | 7140 | 0.760 |
Why?
|
| Social Behavior | 2 | 2020 | 1147 | 0.730 |
Why?
|
| Cognition | 18 | 2024 | 7073 | 0.660 |
Why?
|
| Prefrontal Cortex | 3 | 2019 | 2238 | 0.600 |
Why?
|
| Emotional Intelligence | 1 | 2019 | 135 | 0.570 |
Why?
|
| Nerve Net | 3 | 2024 | 2352 | 0.550 |
Why?
|
| Independent Living | 1 | 2020 | 584 | 0.500 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2016 | 265 | 0.450 |
Why?
|
| Schizotypal Personality Disorder | 3 | 2018 | 289 | 0.440 |
Why?
|
| Neuroglia | 1 | 2019 | 960 | 0.430 |
Why?
|
| Decision Making | 2 | 2024 | 3953 | 0.420 |
Why?
|
| Behavior Therapy | 1 | 2017 | 886 | 0.370 |
Why?
|
| Gyrus Cinguli | 1 | 2017 | 1135 | 0.350 |
Why?
|
| Consensus | 2 | 2017 | 3212 | 0.350 |
Why?
|
| Hallucinations | 2 | 2011 | 373 | 0.340 |
Why?
|
| Brain | 10 | 2024 | 27360 | 0.320 |
Why?
|
| Young Adult | 23 | 2024 | 60066 | 0.310 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2018 | 6029 | 0.310 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2007 | 251 | 0.300 |
Why?
|
| DiGeorge Syndrome | 2 | 2007 | 187 | 0.300 |
Why?
|
| Computer-Assisted Instruction | 1 | 2010 | 366 | 0.290 |
Why?
|
| Schizophrenia, Childhood | 1 | 2007 | 4 | 0.280 |
Why?
|
| Adult | 32 | 2024 | 223646 | 0.280 |
Why?
|
| Smell | 1 | 2009 | 260 | 0.280 |
Why?
|
| Axons | 1 | 2015 | 1677 | 0.270 |
Why?
|
| Touch | 1 | 2009 | 316 | 0.270 |
Why?
|
| Learning | 1 | 2016 | 1759 | 0.260 |
Why?
|
| Phenotype | 1 | 2024 | 16726 | 0.260 |
Why?
|
| Humans | 64 | 2024 | 768166 | 0.260 |
Why?
|
| Disease Progression | 3 | 2024 | 13671 | 0.250 |
Why?
|
| Reward | 2 | 2024 | 981 | 0.250 |
Why?
|
| Aspartic Acid | 2 | 2019 | 577 | 0.240 |
Why?
|
| Social Support | 1 | 2015 | 2193 | 0.240 |
Why?
|
| Male | 37 | 2024 | 364719 | 0.230 |
Why?
|
| Social Adjustment | 3 | 2017 | 635 | 0.220 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2024 | 36743 | 0.220 |
Why?
|
| Chromosomes, Human, Pair 22 | 4 | 2010 | 348 | 0.210 |
Why?
|
| Cerebral Cortex | 2 | 2022 | 5812 | 0.210 |
Why?
|
| Female | 36 | 2024 | 397192 | 0.210 |
Why?
|
| Psychometrics | 3 | 2012 | 3063 | 0.190 |
Why?
|
| Anxiety | 3 | 2024 | 4672 | 0.180 |
Why?
|
| Cluster Analysis | 3 | 2017 | 2732 | 0.170 |
Why?
|
| Choroid Plexus | 1 | 2023 | 249 | 0.170 |
Why?
|
| Adolescent | 17 | 2024 | 89169 | 0.170 |
Why?
|
| Glycine Dehydrogenase (Decarboxylating) | 1 | 2019 | 15 | 0.170 |
Why?
|
| Glycine Agents | 1 | 2019 | 16 | 0.170 |
Why?
|
| Chromosome Deletion | 4 | 2010 | 1385 | 0.160 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2019 | 2420 | 0.150 |
Why?
|
| Middle Aged | 16 | 2024 | 223492 | 0.140 |
Why?
|
| Nootropic Agents | 1 | 2018 | 159 | 0.140 |
Why?
|
| Choline | 1 | 2019 | 522 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 939 | 0.140 |
Why?
|
| Creatine | 1 | 2019 | 427 | 0.140 |
Why?
|
| Mental Recall | 1 | 2023 | 1226 | 0.140 |
Why?
|
| Perceptual Disorders | 1 | 2018 | 199 | 0.130 |
Why?
|
| Analysis of Variance | 3 | 2015 | 6229 | 0.130 |
Why?
|
| Amygdala | 1 | 2024 | 1380 | 0.130 |
Why?
|
| Glycine | 1 | 2019 | 672 | 0.130 |
Why?
|
| Psychomotor Performance | 1 | 2024 | 1892 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2024 | 1168 | 0.120 |
Why?
|
| Multifactorial Inheritance | 2 | 2022 | 1422 | 0.120 |
Why?
|
| Thalamus | 1 | 2021 | 1047 | 0.120 |
Why?
|
| Myelin Sheath | 1 | 2019 | 652 | 0.120 |
Why?
|
| Fear | 1 | 2024 | 1495 | 0.120 |
Why?
|
| Anxiety Disorders | 2 | 2019 | 2748 | 0.120 |
Why?
|
| Aging | 1 | 2013 | 8744 | 0.120 |
Why?
|
| Severity of Illness Index | 6 | 2024 | 15948 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2019 | 903 | 0.110 |
Why?
|
| Parietal Lobe | 1 | 2019 | 866 | 0.110 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 881 | 0.110 |
Why?
|
| Auditory Perception | 1 | 2018 | 587 | 0.110 |
Why?
|
| Psychopathology | 2 | 2019 | 434 | 0.100 |
Why?
|
| Frontal Lobe | 2 | 2016 | 1426 | 0.090 |
Why?
|
| Remedial Teaching | 1 | 2010 | 16 | 0.090 |
Why?
|
| Affect | 1 | 2019 | 1495 | 0.090 |
Why?
|
| Motivation | 1 | 2020 | 2020 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1443 | 0.090 |
Why?
|
| Visual Perception | 1 | 2018 | 1402 | 0.080 |
Why?
|
| Quality of Life | 3 | 2022 | 13490 | 0.080 |
Why?
|
| Delusions | 1 | 2011 | 300 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5315 | 0.080 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 3780 | 0.080 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2024 | 3729 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2019 | 22291 | 0.070 |
Why?
|
| Antipsychotic Agents | 2 | 2018 | 3081 | 0.070 |
Why?
|
| Age Factors | 2 | 2015 | 18412 | 0.070 |
Why?
|
| Neuronal Plasticity | 1 | 2016 | 1448 | 0.070 |
Why?
|
| Cerebellum | 3 | 2024 | 1522 | 0.070 |
Why?
|
| Psychotherapy, Group | 1 | 2010 | 417 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 20227 | 0.070 |
Why?
|
| Genetic Counseling | 1 | 2010 | 635 | 0.070 |
Why?
|
| Evoked Potentials, Auditory | 2 | 2021 | 533 | 0.070 |
Why?
|
| Personality | 1 | 2010 | 559 | 0.070 |
Why?
|
| Massachusetts | 2 | 2016 | 8890 | 0.060 |
Why?
|
| Depression | 1 | 2006 | 8230 | 0.060 |
Why?
|
| Mood Disorders | 2 | 2022 | 1129 | 0.060 |
Why?
|
| Research Design | 2 | 2024 | 6211 | 0.060 |
Why?
|
| Intelligence | 2 | 2007 | 926 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2015 | 2783 | 0.060 |
Why?
|
| Family | 1 | 2014 | 3209 | 0.060 |
Why?
|
| Internet | 1 | 2016 | 3110 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2013 | 2118 | 0.050 |
Why?
|
| Linear Models | 1 | 2013 | 5884 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2006 | 1001 | 0.050 |
Why?
|
| Personality Inventory | 1 | 2006 | 1018 | 0.050 |
Why?
|
| Models, Psychological | 1 | 2007 | 825 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 8054 | 0.050 |
Why?
|
| Off-Label Use | 1 | 2024 | 185 | 0.050 |
Why?
|
| Cadmium | 1 | 2023 | 217 | 0.050 |
Why?
|
| Psychotherapy | 1 | 2010 | 1654 | 0.050 |
Why?
|
| Social Class | 1 | 2010 | 2008 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2012 | 1988 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2018 | 4818 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2024 | 39348 | 0.040 |
Why?
|
| Dopamine | 1 | 2007 | 1592 | 0.040 |
Why?
|
| Methylphenidate | 1 | 2024 | 480 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 15454 | 0.040 |
Why?
|
| Neurons | 1 | 2019 | 9514 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2007 | 1200 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2007 | 1776 | 0.040 |
Why?
|
| Interview, Psychological | 2 | 2012 | 810 | 0.040 |
Why?
|
| International Cooperation | 1 | 2024 | 1436 | 0.040 |
Why?
|
| Aged | 4 | 2019 | 171504 | 0.040 |
Why?
|
| Attention | 1 | 2007 | 2424 | 0.030 |
Why?
|
| Rabbits | 1 | 2022 | 4772 | 0.030 |
Why?
|
| Space Perception | 1 | 2018 | 466 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1760 | 0.030 |
Why?
|
| Risk Factors | 2 | 2016 | 74944 | 0.030 |
Why?
|
| Motion Perception | 1 | 2018 | 379 | 0.030 |
Why?
|
| Random Allocation | 1 | 2019 | 2396 | 0.030 |
Why?
|
| Comorbidity | 3 | 2015 | 10590 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 24315 | 0.030 |
Why?
|
| Social Work | 1 | 2015 | 158 | 0.030 |
Why?
|
| Time Factors | 1 | 2016 | 40218 | 0.030 |
Why?
|
| Patient Dropouts | 1 | 2015 | 411 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2014 | 259 | 0.030 |
Why?
|
| Pattern Recognition, Visual | 1 | 2018 | 826 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 1008 | 0.020 |
Why?
|
| United States | 1 | 2020 | 73039 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2018 | 41754 | 0.020 |
Why?
|
| Hippocampus | 1 | 2024 | 3785 | 0.020 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2018 | 1489 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2021 | 3117 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 2048 | 0.020 |
Why?
|
| Mass Screening | 1 | 2006 | 5458 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 65371 | 0.020 |
Why?
|
| Panic Disorder | 1 | 2012 | 613 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 6316 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2022 | 3589 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 14783 | 0.020 |
Why?
|
| Communication | 1 | 2022 | 3905 | 0.020 |
Why?
|
| Child | 4 | 2010 | 80917 | 0.020 |
Why?
|
| Child Behavior Disorders | 1 | 2010 | 812 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2021 | 6314 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2019 | 12465 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2015 | 2523 | 0.010 |
Why?
|
| Septum Pellucidum | 1 | 2004 | 55 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2010 | 2357 | 0.010 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 26379 | 0.010 |
Why?
|
| Cephalometry | 1 | 2004 | 380 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 13014 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2024 | 54926 | 0.010 |
Why?
|
| Corpus Callosum | 1 | 2004 | 753 | 0.010 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 4423 | 0.010 |
Why?
|
| Syndrome | 1 | 2004 | 3272 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 2004 | 1424 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 4249 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 6894 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 9613 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 13045 | 0.010 |
Why?
|
| Animals | 1 | 2022 | 169246 | 0.010 |
Why?
|